NFKB1 and COVID-19: We previously showed that Sulindac, a non-steroidal (NSAID) drug that interacted with a key human transcription factor NFkB leading to its suppression that might have the potential to significantly control COVID-19, which needs to be ascertained throughclinical studies [1].